Refractory Post-Operative Wound Infection by Arthrographis Kalrae: A Case Report and Review of Literature
##plugins.themes.bootstrap3.article.main##
Arthrographis kalrae (A. Kalrae) infections, although rare, have often demonstrated an extended clinical course. We report a case of refractory post-operative wound infection with A. Kalrae after radical soft tissue and femur resection following total femoral replacement. Identification of A. Kalrae was done based on detailed microscopic and phenotypic characteristics and biochemical tests. Additionally, it was confirmed with sequencing. Although antifungal therapy was started on the basis of the breakpoints observed, clinical failure was met. However, wound infection was subsequently controlled with extensive tissue debridement and a combination of antifungal drug therapy over a period of 33 weeks. The rarity of global data about such unusual fungal infections adds to diagnostic and therapeutic challenges.
Downloads
Introduction
Arthrographis kalrae (A. kalrae) was first isolated in 1938 in northern France from an onychomycotic lesion. Kochet described it as a new species, and it was named as A. langeroni [1]. In India, Tewari and Macpherson reported the first case in 1960 from the sputum sample of a patient with an indistinct respiratory illness [2]. They had reported it as Oidiodendron kalrai [2]. Subsequently, A. langeroni and O. kalrae were accommodated in A. kalrae [3]. Although a diversified group of fungi is established to cause cutaneous, subcutaneous, or systemic infections in immunocompetent as well as immunocompromised individuals, sub-cutaneous hyalohyphomycosis caused by A. kalrae is unusual. To the best of our knowledge, we describe the first case of subcutaneous infection by A. kalrae in an immunocompromised young adult in India.
Case Description
A 17-year-old male presented left thigh swelling and pain, with associated redness and skin pigmentation for the past four months. Upon investigation, he was diagnosed with osteosarcoma (High Grade, Stage II) of left femur. No metastases were noted in lungs following chest CT scan, however multiple deep venous thromboses were present in left lower limb, for which he was put on antiplatelet drugs. Patient was treated with adjuvant chemotherapy for osteosarcoma. He also underwent left thigh radical soft tissue and femur resection following total femoral replacement one month prior (Day 1). However, wound was non-healing and was associated tissue necrosis. Two rounds of irrigation and debridement were done for limb salvage, and specimens of wound cultures were taken (Day 25 and Day 32). Despite this, wound healing was poor with progressive necrosis.
Six surgical swabs were sent to the laboratory for Gram and ZN staining, aerobic and anaerobic bacteria culture, acid-fast bacteria culture, and fungal stain and culture (Day 32). Gram staining showed pus cells, even so bacteria or yeast was not detected. ZN stain smear was negative for acid-fast bacilli. However, few hyaline hyphae were appreciated in 10% KOH stain and calcofluor white stain. The patient was immediately started on itraconazole (100 mg OD) (Day 33). Specimens were inoculated on Blood agar, Chocolate agar, MacConkey agar, and 4 sets of Sabouraud’s Dextrose agar (SDA) with chloramphenicol (0.05 mg/ml). No growth was observed at the end of 24 hours in any bacterial culture plates, which were re-incubated for another 24 hours. On day 3 of inoculation (Day 35), a handful of creamy, moist colonies was seen on the SDA plates kept at 37 °C. However, growth was not detected on the SDA plates kept at 25 °C. On day 6 of incubation (Day 38), growth was observed in plates kept at 25 °C. The initial colonies were cream-coloured and glabrous. It gradually turned velvety, maize in colour, and eventually formed a yellowish powdery colony with soft and frangible texture after 7 days (Day 39; see Figs. 1 and 2).
The fungal isolate could not be identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI TOF MS) (bioMérieux, France). The isolate was, therefore, sent for genomic sequencing, and further morphological and biochemical tests were performed simultaneously. The fungus was found to be weak urease positive, cycloheximide resistant, nitrate non-assimilator, and showed growth at 42°C. The isolate on slide cultures, grown on SDA and potato dextrose agar (PDA), appeared to have irregular or non-branched hyphae with dendritic conidiophores accompanied with chains of rectangular, single-celled arthroconidia. Occasional hyaline sessile conidia were also observed (Fig. 3). The isolate was presumptively identified to belong to the genus Arthrographis.
Pan fungal DNA polymerase chain reaction (PCR) and sequencing were used for the molecular identification of the isolate. The ribosomal DNA (rDNA), genes (18S, 28S, and 5.8S), and the intervening internal transcribed spacer (ITS) regions (ITS1 and ITS2) were targeted. The 3500 DX Analyzer (Thermo Fisher Scientific, Massachusetts, USA) was used. For species identification, sequences were run through GenBank Basic Local Alignment Search Tool (BLAST) searches [4], [5]. BLAST searches confirmed the isolate as A. kalrae with 99.64% identification (GenBank accession no. KM588309.1) of ITS1, ITS2, 5.8S gene, and rRNA gene (Day 47). Antifungal susceptibility test (AFST) was done by the CLSI recommended broth micro-dilution (BMD) method for azoles (fluconazole, voriconazole, posaconazole and itraconazole), amphotericin B, echinocandins (caspofungin, micafungin and anidulafungin) and terbinafine. Breakpoints observed were fluconazole = 16 µg/mL, voriconazole = 0.5 µg/mL, posaconazole = 0.25 µg/mL, itraconazole = 0.5 µg/mL, amphotericin B = 1 µg/mL, caspofungin = 16 µg/mL, micafungin= 8 µg/mL anidulafungin = 8 µg/mL and terbinafine = 0.015 µg/mL (Day 48).
Treatment and Clinical Course
The patient was put on itraconazole (100 mg OD) initially for 2 weeks (Day 33–Day 48). Following the AFST result, liposomal amphotericin B (200 mg thrice a week) was added and continued for 4 weeks (Day 49–Day 80). Despite in vitro sensitive breakpoints, there was no significant wound healing, and the cultures remained positive (Day 70). The patient again underwent left thigh irrigation and debridement (Day 71). AFST was repeated by BMD, and the breakpoints observed were similar to those obtained in the first AFST (Day 80). The patient was put on intravenous liposomal amphotericin B (300 mg daily) along with posaconazole (400 mg OS) and terbinafine (500 mg OD) (Day 80) for 6 weeks (Till Day 122). Vacuum-assisted closure (VAC) dressing was applied. Wound healing started, and the culture of A. kalrae became negative (Day 115). Posaconazole prophylaxis was continued till the patient was operated on for osteosarcoma (Day 138) and then after in a post-operative period with adjuvant chemotherapy for 18 weeks with close follow-up (Day 264). No repeat infection by A. kalrae was noted during the follow-up period.
Discussion
A. kalrae belongs to Genus Arthrographis, a saprophytic fungus that is found in compost and soil globally [6]. A surge in clinical cases of invasive infections caused by A. kalrae has been noted [6]. Thus far, one case with Arthrographis spp. and 20 cases with A. kalrae have been reported with diverse clinical presentations and global distribution (see Table I). This includes seven cases of keratitis [8]–[14], one of which was associated with sinusitis [11], five pulmonary infections [6], [19]–[22], three arthritic infections [15]–[17], and two cases of onychomycoses [1], [7], and one each of endocarditis [18], meningitis [23] and stroke [24].
Reference | Age | Gender | Country | Pathology | Risk factor | Surgery | Antifungal drugs | Outcome |
---|---|---|---|---|---|---|---|---|
[1] | 63 | M | Japan | Onychomycosis | NA | NA | Terbinafine + Miconazole | Relapse |
[6] | 19 | F | France | Pulmonary | Cystic Fibrosis + Lung Transplant | Yes | Caspofungin + Amphotericin B | Death (8 months later) |
[7] | NA | NA | Slovakia | Onychomycosis | NA | NA | NA | NA |
[8] | 23 | F | USA | Keratitis | Contact lens | No | Itraconazole + Amphotericin B | Recovery |
[9] | 42 | F | Germany | Keratitis | Contact lens | Yes | Voriconazole | Chronicity |
[10] | 52 | M | Malaysia | Keratitis | Trauma | Yes | Fluconazole + Amphotericin B | Chronicity |
[11] | 39 | M | China | Keratitis, Sinusitis | Trauma | Yes | Itraconazole + Amphotericin B | Recovery |
[12] | 23 | F | USA | Keratitis | Contact lens | Yes | Itraconazole + Amphotericin B | Chronicity |
[13] | 52 | M | Malaysia | Keratitis | Trauma | Yes | Amphotericin B + Fluconazole | Chronicity |
[14] | 38 | F | Spain | Keratitis | Excimer laser keratomileusis | No | Natamycin + Voriconazole | Chronicity |
[15] | 33 | M | Australia | Knee joint infection | Injury | Yes | Voriconazole + Fluconazole + Posaconazole | Chronicity |
[16] | 68 | M | Italy | Knee joint infection | Diabetes mellitus, injury | No | Voriconazole | Recovery |
[17] | 75 | M | Australia | Knee joint infection | Diabetes mellitus, TKR | Yes | Voriconazole + Terbinafine | NA |
[18] | 50 | F | Spain | Endocarditis | ASD Repair, AVR | Yes | Posaconazole | Relapse |
[19] | 61 | M | Netherlands | Pulmonary | Radiotherapy | Yes | Itraconazole | Recovery |
[20] | 64 | M | USA | Pulmonary | NHL, Allogenic HSCT | No | Voriconazole | Death (3 months later) |
[21] | 51 | F | India | Pulmonary | AIDS | No | NA | NA |
[22] | 7 | M | Italy | Pulmonary | Cystic fibrosis | No | Itraconazole | Recovery |
[23] | 33 | M | USA | Meningitis | AIDS | No | Fluconazole | Death |
[24] | 39 | M | France | Fungal stroke | Malnutrition | No | No | Death (2 days later) |
Present case | 17 | M | India | Sub-cutaneous wound infection | Osteosarcoma, previous surgeries | Yes | Itraconazole + Amphotericin B + Posaconazole + Terbinafine | Chronicity |
Nine cases were reported in Europe, followed by four in the US, two in Malaysia and Australia, and one in India, Japan, and China each. To the best of our knowledge, the present case is the first reported case of post-operative non-healing wound infection caused by A. kalrae. Three of the seven patients with keratitis were soft contact lens wearers; two out of three with knee joint infections had an injury contaminated with soil. Predisposing infection factors, such as AIDS, allogeneic hematopoietic stem cell transplant, malnutrition, radiotherapy, and systemic corticosteroids, were noted in the rest of the patients (see Table I). A. kalrae is believed to enter the human body through the respiratory tract or by inoculation due to trauma [17], [20]. However, the source of A. kalrae infection remained unrecognized in the majority of reported cases. In the present case, the patient had predisposing factors like an immunocompromised state and previous multiple surgeries. There is a possibility of incidental inoculation in the post-operative period. However, it is contingent, and the source of infection remains undetermined.
The presence of uni-celled, cylindrical, hyaline, smooth-walled arthroconidia is a characteristic of the Arthrographis spp. These arthroconidia are formed either directly by fragmentation of undifferentiated hyphae or in new cultures by disjunction and segmentation of fertile hyaline branches. Upon maturation, arthroconidia become large and elongated. Additionally, uni-celled, smooth, spherical hyaline blastoconidia develop directly on the sides of either non-differentiated hyphae or on pedicles [15], [17]. Nonetheless, identification based on microscopy alone is difficult. A. kalrae can be easily confused with Candida albicans because of its primal ivory-colored yeast-like appearance [14]. Furthermore, the presence of abundant arthroconidia can lead to its misidentification as Geotrichum spp. or Trichosporon spp [25]. In previously published reports, phenotypic characteristics and microscopic morphology based on de Hoog and Sigler, as well as Carmichael descriptions, helped in diagnoses [3], [26]. In most cases, species-level identification was confirmed by either MALDI TOF or ITS, D1/D2 sequencing. In the present report, detailed microscopic and phenotypic characteristics and biochemical tests help us reach genus-level identification, which was confirmed by sequencing. MALDI TOF could not identify the causal fungi.
There is no definitive treatment for A. kalrae infections. Thus far, scarcely any reports of A. kalrae infection have covered in vitro AFST data (Table II).
References | Sugiura et al. [1] | Denis et al. [6] | Boan et al. [15] | Sainaghi et al. [16] | Chin-Hong et al. [23] | de Hoog et al. [26] | Present study AFST 1 | Present study AFST 2 |
---|---|---|---|---|---|---|---|---|
No. of isolates | 01 | 01 | 04 | 01 | 01 | 22 | 01 | 01 |
Antifungal drug | Breakpoints (µg/mL) | |||||||
Fluconazole | >64 | >32 | 8–16 | 1 | 8 | – | 16 | 16 |
Voriconazole | – | 0.125 | 0.06–0.5 | 0.030 | – | 0.06–1 | 0.5 | 1 |
Posaconazole | – | 0.50 | 0.25–0.5 | 0.060 | – | <0.03–0.5 | 0.25 | 0.25 |
Itraconazole | 8 | – | 0.25–0.5 | 0.120 | <0.015 | <0.03–2 | 0.25 | 0.5 |
Amphotericin B | 0.5–1 | 0.75 | 0.25–0.5 | 0.5 | 0.25 | 1 – 4 | 1 | 1 |
Caspofungin | – | – | – | 0.250 | – | 0.5–>8 | 16 | 16 |
Micafungin | – | 0.012 | – | 1 | – | <0.015–>8 | 8 | 8 |
Anidulafungin | >16 | 0.047 | – | 0.5 | – | <0.015–>8 | 8 | 8 |
Terbinafine | 0.015 | – | – | – | – | <0.004–0.06 | 0.015 | 0.015 |
Flucytosine | >64 | >32 | >64 | 0.060 | – | – | – | – |
de Hoog et al. [26] studied in vitro AFST patterns of 22 clinical isolates of A. kalrae and terbinafine was found to be the best therapeutic option, followed by the azoles (Posaconazole > Itraconazole/Voriconazole). However, echinocandins showed almost no activity with higher minimum effective concentrations (MECs). Our AFST findings are in accordance with the previously published findings. In the present report, AFST was performed twice using the BMD method with reproducible breakpoints. Despite in vitro sensitive breakpoints, initially, the patient did not respond to the amphotericin B and itraconazole combination. Low levels of drugs in serum and tissues could have possibly contributed to initial clinical failure. However, this cannot be said definitively, as therapeutic drug monitoring was not done. Additionally, the patient was severely immunocompromised, a condition where antifungal agents alone, including high-dose fungicidal agents, are known to be unable to eradicate the fungi [27]. Nonetheless, increased dosages of amphotericin B (concentration-dependent activity), along with combination therapy of terbinafine (BMQ) and posaconazole, helped in wound healing. Molecular characterization of isolated strains was not done for any point mutations. Generally, a treatment period of 3–12 months is advocated [20]. In the present case, treatment with antifungal drugs was given for 33 weeks. Additionally, surgical debridement and VAC dressing were done, which proved to be effective, and no repeat infection by A. kalrae was observed.
Conclusion
We report the first case of a sub-cutaneous A.kalrae infection in India. A. kalrae infections are rare, though they are likely to be under-recognised and under-diagnosed. Knowledge of morphological characteristics and confirmation by molecular investigations are deemed important. Terbinafine appears to be the drug of choice, followed by the azoles; however, further clinical evidence is needed to advocate these deductions. Despite combination therapy of antifungal drugs with sensitive breakpoints along with aggressive treatment, A.kalrae infection can be refractory. Such unusual mycotic infections with a limited corpus delicti add significantly to diagnostic and therapeutic challenges.
References
-
Sugiura Y, Hironaga M. Arthrographis kalrae, a rare causal agent of onychomycosis, and its occurrence in natural and commercially available soils. Med Mycol. 2010;48(2):384–9.
DOI | Google Scholar
1
-
Tewari RP, Macpherson CR. A new dimorphic fungus, Oidiodendron kalrae: morphological and biochemical characteristics. Mycologia. 1971;63:602–11.
DOI | Google Scholar
2
-
Singler L, Carmichael JW. Redisposition of some fungi referred to Oidium microspermum and a review of Arthrographis. Mycotaxon. 1983;18:495–507.
Google Scholar
3
-
National Library of Medicine. (n.d.). BLAST: Basic Local AlignQ1 ment Search Tool. Available from: http://www.ncbi.nlm.nih.gov/BLAST/Blast.cgi.
Google Scholar
4
-
Denis J, Sabou M, Degot T, Candolfi E, Letscher-Bru V. First case of Arthrographis kalrae fungemia in a patient with cystic fibrosis. Med Mycol Case Rep. 2016;14:8–11.
DOI | Google Scholar
5
-
Volleková A, Lisalová M, Poczová M. Arthrographis kalrae—an uncommon causative agent of onychomycosis. Epidemiol Mikrobiol Imunol. 2008;57(2):53–6.
Google Scholar
6
-
Degavre B, Joujoux JM, Dandurand M, Guillot B. First report of mycetoma caused by Arthrographis kalrae: successful treatment with itraconazole. J Am Acad Dermatol. 1997;37(2 Pt 2):318–20.
DOI | Google Scholar
7
-
Thomas BC, Zimmermann S, Völcker HE, Auffarth GU, Dithmar S. Severe Arthrographis kalrae keratomycosis in an immunocompetent patient. Cornea. 2011;30(3):364–6.
DOI | Google Scholar
8
-
Ramli SR, Francis AL, Yusof Y, Khaithir TM. A severe case of Arthrographis kalrae keratomycosis. Case Rep Infect Dis. 2013;2013:851875.
DOI | Google Scholar
9
-
Xi L, Fukushima K, Lu C, Takizawa K, Liao R, Nishimura K. First case of Arthrographis kalrae ethmoid sinusitis and ophthalmitis in the People’s Republic of China. J Clin Microbiol. 2004;42(10):4828–31.
DOI | Google Scholar
10
-
Perlman EM, Binns L. Intense photophobia caused by Arthrographis kalrae in a contact lens-wearing patient. Am J Ophthalmol. 1997;123(4):547–9.
DOI | Google Scholar
11
-
Chow RC, Chong SY, Khaw KW, Yushaniza Y, Kamalden T. A rare case of Arthrographis kalrae keratomycosis in a non-contact lens wearer. Asian J Ophthalmol. 2015;14(1):37–41.
DOI | Google Scholar
12
-
Fernández-Barrientos Y, Ramos-Suárez A, Fernández-Sánchez F, Tirado-Carmona A. Post-laser in situ keratomileusis interface Arthrographis kalrae keratitis. Arq Bras Oftalmol. 2020;83(1):65–8.
DOI | Google Scholar
13
-
Boan P, Arthur I, Golledge C, Ellis D. Refractory Arthrographis kalrae native knee joint infection. Med Mycol Case Rep. 2012;1(1):112–4.
DOI | Google Scholar
14
-
Sainaghi PP, Rossati A, Buccheri C, Bargiacchi O, Garavelli PL, Andreoni S. Arthrographis kalrae arthritis: a new case report. Infez Med. 2015;23(2):192–4.
Google Scholar
15
-
Crawford LC, Kidd SE, Savvoulidis T, Nelson R. Arthrographis kalrae prosthetic joint infection: case report and review of the literature. Pathology. 2021;53(S1):S48–9.
DOI | Google Scholar
16
-
de Diego Candela J, Forteza A, García D, Prieto G, Bellot R, Villar S, et al.. Endocarditis caused by Arthrographis kalrae. Ann Thorac Surg. 2010;90(1):e4–5.
DOI | Google Scholar
17
-
Vos CG, Murk JAN, Hartemink KJ, Daniels JMA, Paul MA, Debets-Ossenkopp YJ. A rare pulmonary infection caused by Arthrographis kalrae. J Med Microbiol. 2012;61(Pt 4):593–5.
DOI | Google Scholar
18
-
Corzo-León DE, Satlin MJ, Soave R, Shore TB, Schuetz AN, Jacobs SE, et al. Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens. Mycoses. 2015;58(6):325–36.
DOI | Google Scholar
19
-
Samal N, Narasimham M, Sahu SK, Padhi S. First case of Arthrographis kalrae pulmonary infection in a patient with AIDS. Microbiol Med. 2021;36(1):9684.
DOI | Google Scholar
20
-
Fiscarelli EV, Ricciotti G, Rossitto M, Pompilio A, Tuccio Guarna Assanti V, Lucidi V. A cystic fibrosis child with lung function decline. J Cyst Fibros. 2019;18(6).
DOI | Google Scholar
21
-
Chin-Hong PV, Sutton DA, Roemer M, Jacobson MA, Aberg JA. Invasive fungal sinusitis and meningitis due to Arthrographis kalrae in a patient with AIDS. J Clin Microbiol. 2001;39(2):804–7.
DOI | Google Scholar
22
-
Pichon N, Ajzenberg D, Desnos-Ollivier M, Clavel M, Gantier JC, Labrousse F. Fatal-stroke syndrome revealing fungal cerebral vasculitis due to Arthrographis kalrae in an immunocompetent patient. J Clin Microbiol. 2008;46(9):3152–5.
DOI | Google Scholar
23
-
Sandoval-Denis M, Giraldo A, Sutton DA, Fothergill AW, Guarro J. In vitro antifungal susceptibility of clinical isolates of Arthrographis kalrae, a poorly known opportunistic fungus. Mycoses. 2014;57(4):247–8.
DOI | Google Scholar
24
-
de Hoog GS, Guarro J, Gene J, Figueras MJ. Atlas of Clinical Fungi. 3rd ed. Utrecht, The Netherlands: CBS-KNAW Fungal Biodiversity Centre; 2011.
Google Scholar
25
-
Chander J. Textbook of medical mycology. In Chapter 6, Antifungal Therapy, 4th ed. New Delhi: Jaypee Brothers Medical Publishers, 2018, pp. 102–23.
Google Scholar
26